Alzheimer Disease
Conditions
Brief summary
The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD).
Detailed description
The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD). At the era of Amyloid, Tau, Neurodegeneration (ATN) biomarkers, amyloid PET fills a need in patients with an atypical or mixed clinical presentation, in particular young patients (\< 65 years old), when the lumbar puncture is contraindicated or not feasible for technical reasons. Importantly, a negative amyloid PET scan discards the diagnosis of AD. Furthermore, early phase imaging of amyloid PET allows to estimate the perfusion neuronal state, increasing the diagnostic value of such PET radiotracer. Its role could be further developed in routine care for the selection and monitoring of promising disease modifiers therapies.
Interventions
OTHERRetrospective study
The data from the PET request form will be collected in each center for this population of patients who have had an amyloid PET scan with flutemetamol and the results of the PET examination reports will also be provided, all data will be made anonymous.
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged = or \> 18 years * Patients who have had an amyloid PET scan with a PET request form including the indications for the examination * Patient informed via a newsletter and non-opposition to the use of their data for research purposes (research objectives clearly explained in the letters)
Exclusion criteria
* Patient opposition to the use of their data for this research
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the indications for Amyloid PET in 7 centers in France to assess the relevance of the examination | 1 day | Correlation between the request and the recommendations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the frequency of positive examinations for the diagnosis of AD | 1 day | Number of positive PET exam |
Countries
France
Outcome results
None listed